Quest Diagnostics (DGX) share prices have seen a significant surge, increasing by 25%. The company has been making continuous strides in the diagnostics industry by improving laboratory testing experiences and broadening access to blood-based screening tests through notable collaborations with industry leaders such as Epic, Guardant Health and Google Cloud. Amid these advancements, Quest Diagnostics has weathered certain criticism over alleged underperformance compared to Dow & encountered reduced holdings by several institutions. However, this hasn't deterred the expansion, evident from consistent stock purchases by banks and other financial entities. Significant announcements include a collaboration involving Epic to transform 2,000 testing centres nationwide, and a partnership with WHOOP to expand consumer health reach. Quest's strategy of reinforcing its foothold in providing personalized care was outlined in a significant Jefferies Healthcare Conference along with promising developments like the launch of a national pharmacogenomic test for precision medicine. Furthermore, increasing dividends and boosting quarterly earnings demonstrate a strong financial position. After achieving a 12-month high, Quest has raised its outlook but also expressed concerns regarding tariff & Medicare Act risks.
Quest Diagnostics DGX News Analytics from Mon, 27 Jan 2025 08:00:00 GMT to Sat, 27 Sep 2025 20:57:04 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 3
